Intravitreal Corticosteroids in the Management of Diabetic Macular Edema

Stephen G. Schwartz, Harry W. Flynn, Ingrid U. Scott

Research output: Contribution to journalArticlepeer-review

28 Scopus citations


Diabetic macular edema (DME) remains an important cause of visual loss worldwide. Corticosteroids have a role in the treatment of some patients with advanced or recurrent DME. The best studied steroids for this indication are triamcinolone acetonide, dexamethasone, and fluocinolone acetonide. All steroids are associated with risks of cataract and intraocular pressure elevation. In addition, intravitreal injection of any medication is associated with such risks as infectious endophthalmitis, which has led to the investigation of various extended-release steroid implants. At this time, no steroid is approved by the United States Food and Drug Administration for the treatment of DME.

Original languageEnglish (US)
Pages (from-to)144-149
Number of pages6
JournalCurrent Ophthalmology Reports
Issue number3
StatePublished - Sep 1 2013

All Science Journal Classification (ASJC) codes

  • Ophthalmology


Dive into the research topics of 'Intravitreal Corticosteroids in the Management of Diabetic Macular Edema'. Together they form a unique fingerprint.

Cite this